Compare Globus Medical Inc. Class A Common Stock (GMED) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs MakeMyTrip Ltd — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while MakeMyTrip Ltd trades at $43.7 (market cap $4.21B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.4× MakeMyTrip Ltd's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and MakeMyTrip Ltd for 12 Days on average.
| GMED | MMYT | |
|---|---|---|
Market Cap | $10.25B | $4.21B |
Volume | 1,108,124 | 954,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $90.73 |
52-Week Low | $58.33 | $36.30 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $9.76B | $4.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
MakeMyTrip (MMYT) trades at $44.70, showing modest daily gains of 0.81%. The stock faces bearish technical signals with mixed earnings performance - beating Q1 2026 estimates but missing Q4 2025 and Q2 2026. Revenue growth remains positive with $978M in 2025, though profitability metrics show volatility. Analyst sentiment remains strongly bullish with a $77 consensus target representing 72% upside potential.
The stock presents significant upside based on analyst targets but faces execution risks amid volatile earnings and rising debt levels. Key catalysts include the planned Indian listing and operational resilience, while risks include geopolitical disruptions and competitive pressures in the travel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
